Summit to focus on blood disorders
Dubai, February 21, 2011
Up to 400 of the region’s top medical experts will discuss recent developments in the medical management of a range of blood disorders and cancers at an upcoming summit in Dubai.
The Middle East Hematology Oncology Summit held under the patronage of Dubai Health Authority (DHA) on February 25 and 26 at Grand Hyatt Dubai.
Qadhi Saeed Al Murooshid, director general of the DHA, said that serious co-operation on the care of patients with cancer and blood disorders was now required between different health authorities and organizations in the Middle east to ensure maximum benefit was made of international developments in the field.
The summit would give participants the opportunity to learn about the latest advances in the investigation, diagnosis, treatment and management of the diseases and their complications, he added.
The summit, which is being held in with the support of DHA and Novartis Oncology, will have a focus on genetic blood disorders, such as thalassemia and sickle cell disease, which are more common in Middle East populations than Northern European ones.
The summit will also focus on a selection of rare cancers in the wake of new advancements in medical management, such as chronic myeloid leukemia (CML), a cancer of the bone marrow, gastrointestinal stromal tumours (GIST), which is a rare cancer of the stomach and gut, and neuroendocrine tumors (NET), a tumor that starts in the small bowel and spreads to the heart.
Advancements include a new drug treatments for patients with GIST and for those suffering from a specific type of CML known as Philadelphia chromosome positive (Ph+ CML), as well as the recent introduction of a new blood test that facilitates the early detection of NET – all of which have improved the prognosis of those suffering from these difficult to treat cancers, a statement said.
“The summit will offer presentations on a wide range of cancers and blood disorders but we plan to focus on those conditions that are more common in Middle East populations, as well as rare cancers that have recently seen great strides in detection and treatment,” said Dr Walid Abdulaziz, medical director, Novartis Oncology Middle East.
“This will ensure that delegates are armed with the most valuable and up-to-date information to assist them in developing first-class management plans in their respective places of work,” he added. – TradeArabia News Service
More Health & Environment Stories
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman
- Al Noor Hospitals targets domestic growth
- Medical panel on the way in Bahrain
- 40pc of UAE adults ‘have hypertension’
- Saudi diabetics urged to stay away from camels
- GCC readies plan to fight heart diseases
- Bahrain opens sickle cell hospital
- Hazardous waste focus for Oman summit
- Infectious viruses to be tracked by satellite in UAE
- Mafraq Hospital names new surgery chief
- Saudi health ministry seals BMJ partnership
- Need for medical simulation training highlighted
- UAE-France discuss healthcare collaboration
- Seha focus on patient centred services
- Saudi-Tokyo firms in wastewater technology JV
- Leading experts at Dubai diabetes conference